There is a particular elegance to the idea behind AOD-9604, and it starts with a simple question: what if you could take the part of growth hormone that burns fat and leave everything else behind?
Human growth hormone is a 191-amino acid protein that does a lot of things. It promotes muscle growth, stimulates bone density, regulates metabolism, and mobilizes fat stores. But full-length HGH also raises IGF-1 levels, can worsen insulin resistance, and carries risks including joint pain, edema, and potentially promoting certain cell proliferations. The side effect profile of exogenous HGH is the reason it has never been widely adopted as a fat-loss therapy despite its clear lipolytic properties.
AOD-9604 was designed to solve that problem. It is a modified fragment of HGH — specifically amino acids 177-191, the C-terminal end of the molecule — with an added tyrosine residue at the beginning for stability. The hypothesis: this small fragment retains the fat-burning signaling activity of full-length HGH but does not bind to the GH receptor in a way that activates the IGF-1 axis or produces the metabolic disruptions associated with full HGH.
That is a compelling premise. The question is whether the data supports it.
I'll be upfront about something: the clinical evidence for AOD-9604 is substantially thinner than what we have for GLP-1 agonists. The Australian trials showed modest results, and the compound never completed the kind of large-scale Phase 3 program that would put it on par with semaglutide or tirzepatide. It may have a role — particularly for people who want a gentler approach or cannot tolerate GLP-1 agonists — but you should go in with realistic expectations about what the evidence actually supports.
How the fragment works
To understand AOD-9604, you need to understand a bit about how growth hormone mobilizes fat.
When HGH binds to its receptor on adipocytes, it activates a signaling cascade that includes beta-3 adrenergic receptor stimulation and hormone-sensitive lipase activation. HSL is the enzyme that breaks down stored triglycerides into free fatty acids and glycerol — a process called lipolysis. These free fatty acids are then released into the bloodstream and can be oxidized by muscle and other tissues for energy.
AOD-9604 appears to stimulate this lipolytic pathway through a mechanism that mimics the C-terminal region's interaction with fat cell membranes. The critical finding from early research is that it does this without activating the full GH receptor signaling complex that leads to IGF-1 elevation.
This distinction matters clinically. IGF-1 is a potent growth factor that stimulates cell proliferation throughout the body. Elevated IGF-1 levels are associated with insulin resistance, joint and soft tissue swelling, and theoretical concerns about promoting abnormal cell growth. By avoiding IGF-1 elevation, AOD-9604 sidesteps the most concerning aspects of HGH therapy.
In preclinical studies, AOD-9604 also showed some evidence of inhibiting lipogenesis — the process by which new fat is synthesized and stored. If confirmed in humans, this would mean AOD-9604 has a dual mechanism: breaking down existing fat stores while reducing the formation of new fat. That is a potentially useful combination for body composition management.
Early animal data also suggested that AOD-9604 does not affect blood glucose levels or insulin sensitivity in the way that full-length HGH does. In obese mouse models, AOD-9604 reduced body fat without altering fasting glucose, insulin levels, or glucose tolerance — reinforcing the fragment hypothesis that you can separate the lipolytic activity from the metabolic disruption.
The Australian clinical trials
AOD-9604's clinical development history is centered in Australia, where it was developed by Metabolic Pharmaceuticals Limited in collaboration with Monash University researchers.
The preclinical work was promising. In obese Zucker rats — a standard model for metabolic research — AOD-9604 reduced body weight and body fat without affecting food intake, IGF-1 levels, or insulin sensitivity. The rats lost fat without eating less, which suggested a genuinely metabolic mechanism rather than an appetite suppression effect.
The Phase 2 clinical trial enrolled approximately 300 obese adults in a randomized, double-blind, placebo-controlled study. Participants received oral AOD-9604 at various doses (1mg, 5mg, 10mg, 20mg) or placebo daily for 12 weeks.
The results were mixed. The overall study did not reach statistical significance for its primary endpoint — the average weight loss across all AOD-9604 groups was not statistically different from placebo when the full population was analyzed. However, a pre-specified subgroup analysis of participants at the 1mg dose showed a statistically significant difference in fat loss by DEXA scan compared to placebo, and there was a trend toward greater weight loss at lower doses that did not follow the expected dose-response pattern.
This inverse dose-response relationship was unusual and complicated the interpretation. In most pharmacological studies, higher doses produce greater effects. The possibility that AOD-9604 might work better at lower doses raised questions about the oral formulation, absorption, and whether the optimal dosing had been identified.
Metabolic Pharmaceuticals conducted additional studies and ultimately submitted AOD-9604 to the Therapeutic Goods Administration in Australia. The compound received regulatory clearance from the TGA as a food-grade supplement ingredient — a classification that acknowledges its safety profile but is distinct from a full therapeutic approval for obesity treatment. The TGA's safety assessment concluded that AOD-9604 has a favorable safety profile with no significant adverse effects identified in the clinical trial data.
I want to be precise about what this means: the TGA clearance establishes safety, not efficacy for a specific therapeutic claim. AOD-9604 did not complete a Phase 3 clinical program for obesity treatment. The development program was halted after the Phase 2 results, and Metabolic Pharmaceuticals eventually shifted its focus to other compounds.
Dosage and research context
In the research community, AOD-9604 is most commonly studied as a subcutaneous injectable formulation rather than the oral form used in the Australian clinical trials. The rationale is straightforward: subcutaneous delivery avoids the first-pass hepatic metabolism and gastrointestinal degradation that can reduce the bioavailability of peptide compounds when taken orally.
The standard research formulation referenced in the literature is a 5mg preparation (ref: 5AD), which is commonly used in research protocols studying the compound's lipolytic effects.
Research protocols typically involve administration on an empty stomach, as food intake can affect peptide absorption and activity. The timing is consistent with the compound's proposed mechanism — stimulating lipolysis when insulin levels are low maximizes the release and oxidation of fatty acids, because elevated insulin suppresses hormone-sensitive lipase activity.
How AOD-9604 compares to GLP-1 agonists
This is where honest assessment matters.
GLP-1 agonists like semaglutide and tirzepatide have produced 15-22% body weight loss in large, multi-year clinical trials enrolling thousands of participants. They have Phase 3 data, cardiovascular outcomes data, FDA approvals, and millions of patients' worth of real-world evidence. AOD-9604 has Phase 2 data with mixed results from trials enrolling hundreds of participants, an incomplete development program, and no therapeutic approval for obesity in any major market.
The clinical evidence gap is enormous, and it would be dishonest to suggest otherwise.
That said, the comparison is not entirely apples to apples. AOD-9604 and GLP-1 agonists work through completely different mechanisms. GLP-1 agonists primarily suppress appetite — they make you eat less. AOD-9604 is proposed to directly stimulate fat mobilization and oxidation without substantially affecting appetite. These are different pharmacological approaches to the same problem.
For some people, this distinction is meaningful. GLP-1 agonists produce significant gastrointestinal side effects — nausea, vomiting, diarrhea, constipation — in 30-40% of users. They can cause the muscle loss concern I've discussed in the context of semaglutide. AOD-9604's side effect profile in clinical trials was essentially equivalent to placebo. No significant nausea, no gastrointestinal disruption, no metabolic disturbance. If you cannot tolerate GLP-1 agonists or prefer to avoid their side effects, the trade-off between a more potent compound with significant side effects and a milder compound with minimal side effects is a reasonable conversation to have with a clinician.
AOD-9604 is also sometimes discussed as a "gateway" fat-loss peptide — a lower-intensity option for people exploring the peptide space who want to begin with something that has a very mild side effect profile. There is some logic to that framing, but I want to be careful not to overstate what the evidence supports.
The honest limitations
In the interest of full transparency, here are the things that give me pause about AOD-9604.
The clinical data is thin. One incomplete Phase 2 program with mixed results is not sufficient to make strong claims about efficacy. The animal data was compelling, but the jump from rodent models to human outcomes did not produce the clear signal that everyone hoped for.
The dose-response was anomalous. The inverse dose-response relationship in the Phase 2 trial has never been fully explained. This could mean the optimal dose was below the range studied, or it could mean the oral formulation had inconsistent bioavailability, or it could mean the effect is genuinely small and the low-dose finding was a statistical artifact. Without additional controlled studies, we cannot distinguish between these explanations.
The development program was abandoned. Metabolic Pharmaceuticals stopped developing AOD-9604 for obesity after the Phase 2 results. In pharmaceutical development, companies abandon compounds for many reasons — including insufficient funding, strategic pivots, and market timing — so abandonment does not necessarily mean the compound does not work. But it does mean we lack the Phase 3 data that would answer the efficacy question definitively.
The oral vs. injectable question remains open. The clinical trials used oral AOD-9604, but the research community predominantly uses injectable formulations. Whether the subcutaneous route produces meaningfully different results than oral administration in humans has not been rigorously established in controlled trials.
Most of what we "know" is extrapolated. The preclinical data — no IGF-1 elevation, no insulin resistance, lipolytic activity, anti-lipogenic effects — is from animal models. The human data confirms safety but does not robustly confirm all of the mechanistic claims in clinical populations.
I share these limitations not to discourage interest in AOD-9604 but because I think you deserve a clear-eyed assessment. In a space where many compounds are promoted with more enthusiasm than evidence, being honest about what the data does and does not show matters.
Where AOD-9604 fits in the landscape
If I were mapping the fat-loss peptide landscape based on evidence quality and expected effect size, the picture is fairly clear.
GLP-1 agonists (semaglutide, tirzepatide, retatrutide) sit at the top — the most clinical data, the largest effect sizes, the most comprehensive metabolic benefits, and the most significant side effects.
AOD-9604 occupies a different position — a compound with an elegant mechanism, a clean safety profile, modest clinical evidence, and likely a more modest effect size. It is not competing with semaglutide for the same clinical role. It is a different tool that may serve a different purpose for different people.
For someone with significant obesity and metabolic comorbidities, the evidence strongly favors a GLP-1 agonist. For someone interested in a gentler approach to body composition optimization with minimal physiological disruption, AOD-9604 may be a reasonable option to discuss with a clinician — with the understanding that the evidence base is less robust.
That positioning is honest, and I think honesty serves everyone better than hype.
Frequently asked questions
Does AOD-9604 actually avoid raising IGF-1?
This is one of the most consistently supported findings in the research. Multiple preclinical studies and the human clinical trial data showed no significant elevation in IGF-1 levels with AOD-9604 administration. The C-terminal region of HGH does not engage the GH receptor the same way the full-length molecule does, so it does not trigger the downstream IGF-1 signaling cascade. This is the primary safety advantage of the fragment approach over full HGH.
How long before you see results?
The Australian clinical trial ran 12 weeks, and the subgroup that showed a statistically significant fat-loss signal demonstrated measurable changes in body composition by DEXA scan within that timeframe. Anecdotal reports from the research community generally describe noticeable body composition changes beginning at 4-8 weeks with consistent use, though individual variation is significant. Unlike GLP-1 agonists, AOD-9604 does not produce dramatic appetite changes or rapid scale weight loss — the effects, if present, tend to be more gradual and more specifically reflected in body fat percentage rather than total body weight.
Can you combine it with GLP-1 agonists?
Because AOD-9604 and GLP-1 agonists work through entirely different mechanisms — direct lipolysis stimulation versus central appetite suppression — there is no pharmacological reason they could not be used concurrently. Some researchers have speculated that the combination might be synergistic, addressing fat loss from both the supply side and the demand side. However, this combination has not been studied in controlled clinical trials, and any such approach should be discussed with a qualified clinician.
Is AOD-9604 the same thing as HGH Fragment 176-191?
This is a common source of confusion. HGH Fragment 176-191 and AOD-9604 are closely related but not identical. Both consist of amino acids 177-191 from the C-terminal region of human growth hormone. However, AOD-9604 includes an additional tyrosine residue at the N-terminal end, which was added to improve stability and activity. In practice, the terms are sometimes used interchangeably in informal contexts, but they are technically distinct molecules. AOD-9604 is the version that was used in the clinical trials and has the TGA safety clearance.
What are the side effects?
This is one of AOD-9604's most appealing characteristics. The side effect profile in clinical trials was essentially equivalent to placebo. No significant nausea, no gastrointestinal disruption, no changes in blood glucose, insulin, or IGF-1 levels, and no serious adverse events attributed to the compound. Some users report mild injection-site irritation with subcutaneous administration, which is common with any injectable peptide and typically resolves quickly. The TGA's safety assessment specifically noted the absence of significant adverse effects.
Why do people call it a "gateway" fat-loss peptide?
The term reflects AOD-9604's position as a lower-intensity option with minimal side effects. People who are new to the peptide space and want to start with something gentle often consider AOD-9604 before moving to more potent compounds like GLP-1 agonists. If you can achieve your body composition goals with a mild compound, there is no need for a more aggressive one. If the results are insufficient, you have learned how your body responds to peptide therapy in general and can make a more informed decision about escalating. I think this is reasonable logic, though I would emphasize that "gateway" should not imply AOD-9604 is merely a stepping stone — for some people, it may be entirely sufficient.